These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1733752)

  • 1. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity.
    Fisher E; Siemes H; Pund R; Wittfoht W; Nau H
    Epilepsia; 1992; 33(1):165-71. PubMed ID: 1733752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity.
    Siemes H; Nau H; Schultze K; Wittfoht W; Drews E; Penzien J; Seidel U
    Epilepsia; 1993; 34(2):332-46. PubMed ID: 8453944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication.
    Löscher W; Nau H; Wahnschaffe U; Hönack D; Rundfeldt C; Wittfoht W; Bojic U
    Epilepsy Res; 1993 Jun; 15(2):113-31. PubMed ID: 8370349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
    Kondo T; Kaneko S; Otani K; Ishida M; Hirano T; Fukushima Y; Muranaka H; Koide N; Yokoyama M
    Epilepsia; 1992; 33(1):172-7. PubMed ID: 1733753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
    Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of infantile spasms with valproate: results of a prospective study.
    Siemes H; Spohr HL; Michael T; Nau H
    Epilepsia; 1988; 29(5):553-60. PubMed ID: 2842127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal metabolism of valproic acid in fatal hepatic failure.
    Kochen W; Schneider A; Ritz A
    Eur J Pediatr; 1983 Oct; 141(1):30-5. PubMed ID: 6416845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. III. Influence of fasting.
    Löscher W; Wahnschaffe U; Hönack D; Drews E; Nau H
    Epilepsy Res; 1993 Dec; 16(3):183-94. PubMed ID: 8119269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolite profiles in patients on high-dose valproate monotherapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsy Res; 1996 Oct; 25(2):107-12. PubMed ID: 8884168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Lockard JS; Thummel KE; Baillie TA
    Drug Metab Dispos; 1986; 14(4):443-53. PubMed ID: 2873992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.
    Lee MS; Lee YJ; Kim BJ; Shin KJ; Chung BC; Baek DJ; Jung BH
    Arch Pharm Res; 2009 Jul; 32(7):1029-35. PubMed ID: 19641884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of valproate dose on formation of hepatotoxic metabolites.
    Anderson GD; Acheampong AA; Wilensky AJ; Levy RH
    Epilepsia; 1992; 33(4):736-42. PubMed ID: 1628592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics.
    Tang W; Abbott FS
    Drug Metab Dispos; 1997 Feb; 25(2):219-27. PubMed ID: 9029053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. I. Biochemical, histopathological and pharmacokinetic studies.
    Löscher W; Wahnschaffe U; Hönack D; Wittfoht W; Nau H
    Epilepsy Res; 1992 Dec; 13(3):187-98. PubMed ID: 1493781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate metabolites and hepatotoxicity in an epileptic population.
    Tennison MB; Miles MV; Pollack GM; Thorn MD; Dupuis RE
    Epilepsia; 1988; 29(5):543-7. PubMed ID: 3137018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid.
    Kassahun K; Abbott F
    Drug Metab Dispos; 1993; 21(6):1098-106. PubMed ID: 7905390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Irreversible valproate-associated liver failure].
    Siemes H; Nau H; Seidel U; Gramm HJ
    Monatsschr Kinderheilkd; 1992 Dec; 140(12):869-75. PubMed ID: 1491708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.